**Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program**

Richard B Warren, 1 Howard Sofen, 2 Shinichi Imakufo, 3 Jacek C Szepeiwski, 1 Andrew Blauvelt, 1 Lynda Spelman, 1 Jessica Tom, 1 Alex Buck, 3 Subhashis Banerjee, 4 Alan Menter

1Dermatology Center, St. Louis Royal HS Foundation Trust, St. Louis Children's Hospital, St. Louis, MO, USA, 2CSL School of Medicine and Dermatology Research Institute, The University of Nevada, Las Vegas, NV, USA, 3CSL School of Medicine and Dermatology Research Institute, Los Angeles, CA, USA, 4Takeda University Hospital, Fukoka, Japan, 5Theraxic Medical Research Center, Portland, OR, USA

**Synopsis**

- *Deucravacitinib* (TAK-958) is an oral, selective, potent dual inhibitor of protein kinase C (PKC) α and PKC δ, which are responsible for the activation of a key epidermal growth factor receptor (EGFR) pathway.
- 2-year results from 3 phase III studies (POETYK PSO-1, PSO-2, LTE) have been presented.
- The Incidence rates for AEs of interest were generally consistent with findings from clinical trials, with the exception of events related to COVID-19.
- In this study, the incidence of AEs of interest was similar at 1 year and 2 years, except for events related to COVID-19.
- Deucravacitinib was well tolerated.

**Objectives**

- To evaluate the long-term safety and efficacy of deucravacitinib in patients with plaques psoriasis, including patients who reached Week 60 or discontinued by October 1, 2021.
- To compare the safety and efficacy data from the POETYK LTE study with long-term safety data from previous clinical trials.

**Methods**

- **Study design:** The study was a randomized, open-label study with a 1 year lead-in period followed by a 2-year extension period (LTE) phase.
- **Randomization:** Patients were randomized 1:2:1 to placebo or deucravacitinib 4 mg QD or 6 mg QD, respectively.
- **Endpoints:** The primary endpoints were PASI 75, PASI 90, and static Physician’s Global Assessment (sPGA) 0/1 response rates at the start of LTE for PASI 75, PASI 90, and sPGA 0/1 were maintained for up to 2 years.
- **Safety outcomes:** Included total adverse events (AEs) and select AEs of interest, including infections, major adverse cardiovascular events (MACE), venous thromboembolism (VTE) events, herpes zoster, and nonmelanoma skin cancer (NMSC).

**Results**

- **Efficacy:** Deucravacitinib was well tolerated.
- **Safety:** The incidence of AEs of interest was similar at 1 year and 2 years, except for events related to COVID-19.
- **Conclusion:** Deucravacitinib treatment provided sustained safety and efficacy for up to 2 years.

**References and Supplemental Material**

- **Disclosures:**
  - The authors have indicated no significant interest with commercial supporters.
  - The authors declare no conflict of interest.

**Conclusions**

- The results of the POETYK LTE study confirm the long-term safety and efficacy of deucravacitinib in patients with plaque psoriasis.
- The overall incidence of AEs of interest was similar at 1 year and 2 years, except for events related to COVID-19.
- Deucravacitinib was well tolerated.
- Deucravacitinib treatment provided sustained safety and efficacy for up to 2 years.

**Acknowledgments**

- The authors gratefully acknowledge the contributions of all the patients, investigators, and sites.
- The authors thank the patients who participated in the study and the investigators who supported the study.
- The authors thank the study nurses and other personnel who contributed to the conduct of the study.
- The authors thank the research staff, including the data managers, statisticians, and the clinical research coordinators.
- The authors thank the patients who participated in the study and the investigators who supported the study.
- The authors thank the research staff, including the data managers, statisticians, and the clinical research coordinators.
- The authors thank the patients who participated in the study and the investigators who supported the study.
- The authors thank the research staff, including the data managers, statisticians, and the clinical research coordinators.
- The authors thank the patients who participated in the study and the investigators who supported the study.
- The authors thank the research staff, including the data managers, statisticians, and the clinical research coordinators.
- The authors thank the patients who participated in the study and the investigators who supported the study.